Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy

Cancer

Volumn 118, Issue 11, 2012, Pages 2935-2943

  Wettergren, Yvonne ^a   Carlsson, Göran ^a   Odin, Elisabeth ^a   Gustavsson, Bengt ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

5 FU leucovorin; dihydropyrimidine dehydrogenase; dihydrouracil uracil ratio; DPYD; oxaliplatin

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; DIHYDROURACIL; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; URACIL;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BODY MASS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CATION EXCHANGE; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIARRHEA; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRY EYE; ENZYME ACTIVITY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; SCORING SYSTEM; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SEX RATIO; SINGLE DRUG DOSE; SKIN DISEASE; STOMATITIS; THROMBOCYTOPENIA; URINALYSIS; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DIARRHEA; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; SEX CHARACTERISTICS; THROMBOCYTOPENIA; URACIL;

EID: 84861337759     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26595     Document Type: Article

References (29)

1. Eidinoff ML, Knoll JE, Klein D,. Effect of 5-fluorouracil on the incorporation of precursors into nucleic acid pyrimidines. Arch Biochem Biophys. 1957; 71: 274-275.
2. Carlsson G, Graf W, Gustavsson BG, Glimelius B, Pahlman L, Spears PC,. Sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic gastrointestinal cancer. Eur J Cancer. 1990; 26: 874-876.
3. Sorbye H, Dahl O,. Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic colorectal cancer. Acta Oncol. 2003; 42: 827-831.
4. van Kuilenburg AB, Meinsma R, van Gennip AH,. Pyrimidine degradation defects and severe 5-fluorouracil toxicity. Nucleosides Nucleotides Nucleic Acids. 2004; 23: 1371-1375.
5. Diaz R, Segura A, Aparicio J, Calderero V, Guerrero A, Pellin L,. Lethal toxicity after 5-fluorouracil chemotherapy and its possible relationship to dihydropyrimidine dehydrogenase deficiency: a case report and review of the literature. J Chemother. 2004; 16: 599-603.
6. Jiang H, Lu J, Ji J,. Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels. Br J Pharmacol. 2004; 141: 616-623.
7. Jiang H, Lu J, Jiang J, Hu P,. Important role of the dihydrouracil/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics. J Clin Pharmacol. 2004; 44: 1260-1272.
8. Etienne MC, Lagrange JL, Dassonville O, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol. 1994; 12: 2248-2253.
9. Boisdron-Celle M, Remaud G, Traore S, et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett. 2007; 249: 271-282.
10. Morel A, Boisdron-Celle M, Fey L, et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther. 2006; 5: 2895-2904.
11. 13C-uracil breath test. Clin Cancer Res. 2004; 10: 2652-2658.
12. Ciccolini J, Mercier C, Blachon MF, Favre R, Durand A, Lacarelle B,. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity. J Clin Pharm Ther. 2004; 29: 307-315.
13. Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000; 124: 979-994.
14. JMP version 8.0. Cary, NC: SAS.
15. Hayashi K, Kidouchi K, Sumi S, et al. Possible prediction of adverse reactions to pyrimidine chemotherapy from urinary pyrimidine levels and a case of asymptomatic adult dihydropyrimidinuria. Clin Cancer Res. 1996; 2: 1937-1941.
16. Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ,. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer. 1995; 75: 11-17.
17. Chansky K, Benedetti J, Macdonald JS,. Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer. 2005; 103: 1165-1171.
18. Kaminski A, Joseph D, Elsaleh H,. Differences in toxicity across gender in patients treated with chemoradiation for rectal cancer. Australas Radiol. 2007; 51: 283-288.
19. Milano G, Etienne MC, Cassuto-Viguier E, et al. Influence of sex and age on fluorouracil clearance. J Clin Oncol. 1992; 10: 1171-1175.
20. Gamelin E, Boisdron-Celle M, Guerin-Meyer V, et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol. 1999; 17: 1105-1110.
21. Ramani VS, Gollins SW, Wong H,. Weekly fluorouracil at 425 mg/m(2) plus low-dose folinic acid for 24 weeks as adjuvant treatment for colorectal cancer: assessment of toxicity and delivery. Clin Oncol (R Coll Radiol). 2006; 18: 649-657.
22. Gusella M, Crepaldi G, Barile C, et al. Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer. Ann Oncol. 2006; 17: 1656-1660.
23. Sloan JA, Goldberg RM, Sargent DJ, et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol. 2002; 20: 1491-1498.
24. Ezzeldin HH, Lee AM, Mattison LK, Diasio RB,. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res. 2005; 11: 8699-8705.
25. Amstutz U, Farese S, Aebi S, Largiader CR,. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy. J Exp Clin Cancer Res. 2008; 27: 54.
26. Thomas HR, Ezzeldin HH, Guarcello V, Mattison LK, Fridley BL, Diasio RB,. Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism. Pharmacogenet Genomics. 2007; 17: 973-987.
27. Thomas HR, Ezzeldin HH, Guarcello V, Mattison LK, Fridley BL, Diasio RB,. Genetic regulation of beta-ureidopropionase and its possible implication in altered uracil catabolism. Pharmacogenet Genomics. 2008; 18: 25-35.
28. Fidlerova J, Kleiblova P, Bilek M, et al. Contribution of dihydropyrimidinase gene alterations to the development of serious toxicity in fluoropyrimidine-treated cancer patients. Cancer Chemother Pharmacol. 2010; 65: 661-669.
29. Arnaud MJ,. Pharmacokinetics and metabolism of natural methylxanthines in animal and man. Methylxanthines: Handb Exp Pharmacol. 2011; 200: 33-91.